• Product name
  • Description
    Goat polyclonal to USP6
  • Host species
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide:


    , corresponding to C terminal amino acids 773-786 of Human USP6.

  • Positive control
    • Human placenta
  • General notes
    GenBank Accession Number – NP_004496. Gene Ontology terms - lysosomal cysteine-type endopeptidase; nucleic acid binding; deubiquitination; oncogenesis; protein modification.



Our Abpromise guarantee covers the use of ab4553 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 3 µg/ml. Detects a band of approximately 90 kDa (predicted molecular weight: 90 kDa).Can be blocked with Human USP6 peptide (ab23054). An additional band of 50kDa was consistently observed, however this band was not blocked by the immunizing peptide and it is therefore a non-specific signal. We call for caution when used for other assays than Western blot.


  • Function
    Deubiquitinase with an ATP-independent isopeptidase activity, cleaving at the C-terminus of the ubiquitin moiety. Catalyzes its own deubiquitination. In vitro, isoform 2, but not isoform 3, shows deubiquitinating activity. Promotes plasma membrane localization of ARF6 and selectively regulates ARF6-dependent endocytic protein trafficking. Is able to initiate tumorigenesis by inducing the production of matrix metalloproteinases following NF-kappa-B activation.
  • Tissue specificity
    Testis specific. Expressed in various cancer cell lines.
  • Involvement in disease
    Note=A chromosomal aberration involving USP6 is a common genetic feature of aneurysmal bone cyst, a benign osseous neoplasm. Translocation t(16;17)(q22;p13) with CDH11. The translocation generates a fusion gene in which the strong CDH11 promoter is fused to the entire USP6 coding sequence, resulting in USP6 transcriptional up-regulation.
  • Sequence similarities
    Belongs to the peptidase C19 family.
    Contains 1 Rab-GAP TBC domain.
  • Domain
    The Rab-GAP TBC domain lacks GTPase activator activity but is necessary for interaction with ARF6.
  • Post-translational
    Monubiquitinated; ubiquitination is calmodulin and calcium dependent.
  • Cellular localization
    Cell membrane. Cytoplasm. Endosome. Localizes to the plasma membrane and to filamentous structures within the cell corresponding to ARF6 regulated tubular endosomes. Activation of RAC1 and CDC42 can direct the relocalization of USP6 to the plasma membrane in a manner that depends on the integrity of the actin cytoskeleton.
  • Information by UniProt
  • Database links
  • Alternative names
    • Deubiquitinating enzyme 6 antibody
    • HRP1 antibody
    • Proto-oncogene TRE-2 antibody
    • TRE17 antibody
    • TRE2 antibody
    • Ubiquitin carboxyl-terminal hydrolase 6 antibody
    • Ubiquitin specific protease 6 antibody
    • Ubiquitin thiolesterase 6 antibody
    • Ubiquitin-specific-processing protease 6 antibody
    • UBP6_HUMAN antibody
    • USP6 antibody
    see all


  • All lanes : Anti-USP6 antibody (ab4553) at 2 µg/ml

    Lane 1 : Human placenta lysate in RIPA buffer
    Lane 2 : Human placenta lysate in RIPA buffer with immunizing peptide

    Lysates/proteins at 35 µg per lane.

    Developed using the ECL technique.

    Predicted band size: 90 kDa
    Observed band size: 90 kDa
    Additional bands at: 50 kDa (possible non-specific binding)


This product has been referenced in:
  • Urso ML  et al. Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J Appl Physiol 101:1136-48 (2006). Read more (PubMed: 16763108) »
See 1 Publication for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A


Thank you for contacting us. This antibody is guaranted for use in WB for Human samples. The antibody was used at a concentration of 1-3 ug/ml, incubated overnight at 4 degrees. Blocking was done with 5% BSA. There is a non-specific band that appears at 50 kD but you should get a specific band at 90kD.
I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.
Use our products? Submit an Abreview. Earn rewards!

Read More


Thank you for your enquiry. ab4553 is a fast track antibody. I have enclosed the fast track policy below. Essentially it is an antibody that we already sell at a reduced price since it is not fully characterized, therefore, I cannot send you a sample aliquot. We have tested it in a peptide ELISA and have not fully characterized it in Western nor tested it in IP. Many customers purchase fast-track antibodies, however, and I encourage you to read the details below. If you prove that the antibody does or does not work then you receive enough Abpoints to cover the cost of the antibody and apply them towards a new antibody. As far as the problem you are having being able to see the IgG light chain you can try running a non-reduced non-denatured gel so that the IgG runs at 150 kD or you can covalently link your antibody to the beads so it does not come off with the protein when you elute it. either of these methods can eliminate the your problem of seeing the IgG light chain. Here is the fast-track information below: Fast-Track Antibodies Our customers have told us that they want cutting-edge products released quickly so that their research is not impeded. Abcam is therefore pleased to be able to offer researchers access to products that are still in development. Fast-Track antibodies are immunogen affinity purified and are shown by ELISA to have high titre values against their immunogen. We are currently testing them for use in Western blotting. At this stage, there can be delays. We sometimes experience problems in searching for / developing the correct lysate or knock-out cell-line. In addition, certain products can be difficult to characterise, due, for instance, to low expression levels or a lack of expression in easily available lysates. We realize that these products might be very suitable for your research and do not wish to delay this; therefore, we release them early with the following understanding: As Fast-Track antibodies are not yet fully characterized we are unable to offer our normal level of technical support. We cannot guarantee that the antibody will work in any application other than ELISA against the immunizing peptide and therefore we are unable to offer a refund if the antibody does not work in your application. However, Fast-Track antibodies are offered at a reduced price. Feedback reward We would greatly appreciate your feedback on these antibodies, whether positive or negative. We will award 1,000 Abpoints to the first researcher who sends us positive feedback (including an image and details of materials & methods). Conclusive negative feedback that leads us to withdraw the antibody will also be rewarded with 1,000 Abpoints. Other useful positive and negative feedback will be rewarded with 50 Abpoints. All awards are subject to approval by Abcam scientists and provision of suitable data. Please submit feedback to fast-track@abcam.com I hope this information helps, please do not hesitate to contact us if you need any more advice or information.

Read More


Sign up